Scientist In vivo Pharmacology

CURRICULUM VITAE

RAMU YARAMASU M.Pharm

************@*****.***

***********@*****.***

Mobile: +45 71663664

C/o Nazar

Hessensgade 21, 1th

**** ********** *, *******

EDUCATIONAL QUALIFICATION

Qualification University/Board Year of

passing

Master of Pharmacy Annamali University, India 2008

(Pharmacology)

Bachelor of Rajiv Gandhi University, India 2005

Pharmacy

Diploma in Karnataka Drug Control 2001

Pharmacy Board-Bangalore, India

reSEaRCH eXPERIENCE

> Worked as Research Executive (In-vivo Pharmacology), Laila Nutraceuticals

Limited, Vijayawada, A.P (India) 2013-2014, involved in the successful

herbal drug discovery of various diseases like Osteoarthritis, Rheumatoid

arthritis, Hypertension and Metabolic disorders.

> As Research Associate in Drug Discovery Biology (In-vivo Pharmacology),

Suven Life Sciences Limited, Hyderabad, A.P (India), 2009-2013 worked in

the novel drug targets for various CNS neurodegenerative diseases like

Alzheimer's disease, Schizophrenia, Parkinsonism and Depression.

> As Research Trainee Pharmacology in Biology Deportment (In-vivo

Pharmacology), Sigma Institute of Clinical Research Hyderabad, A.P

(India), 2008-2009 results to successful development and validation of

animal models for pain and inflammation and Gastro intestinal safety

models in rats.

ACHIEVEMENTS IN PROFESSIONAL EXPERIENCE

Preclinical Model development for

V Cognitive deficits of Alzheimer's disease

in Rats and Mice.

V Depression, Psychosis and Anxiety Models in

Rats and Mice.

V Neuropathic Pain Models in Rats.

V Inflammation Models in Rats.

V Metabolic Disorders in Rats.

CAREER SUMMARY

Handful experience in various Preclinical Animal models for rapid In-vivo

screening of Novel Chemical Entities for diverse Pharmacological areas like

CNS, Pain and Inflammation, Metabolic disorders and an Expert Having more

than six years of experience in their Model development and Safety

Pharmacological Assessment on vital organ systems like CNS, CVS and GI

system.

Preclinical Screening of Novel Chemical Entities for efficacy and safety in

Cognition, Depression, Anxiety and Psychosis areas by

1. Forced swim test (Depression)

2. Tail suspension test (Depression)

3. Novelty induced hypophagia (Depression)

4. Dominant submassive task (Depression)

5. Novel object recognition task (Cognition)

6. T-maze task (Cognition)

7. Radial arm maze task (Cognition)

8. Passive avoidance task (Cogntion)

9. Social recognition task (Cognition)

10. Vogel conflict test (Anxiety)

11. Elevated T-maze (Anxiety)

12. Open field task (Anxiety)

13. Elevated plus maze test (Anxiety)

14. MK-801 induced hyper locomotion (Psychosis)

15. MK-801 induced stereotypic behaviour (Psychosis)

Anti convulsant activity.

Preclinical Screening of Novel Chemical Entities for efficacy and safety in

Pain and Inflammation

1. Carrageenan-induced paw edema.

2. CFA adjuvant - induced inflamatory pain.

3. Formalin induced acute pain in rats.

4. Tail flick method.

5. Hot plate method.

6. Acetic acid induced writhing in mice.

7. Partial Sciatic nerve ligation.

8. Sciatic nerve ligation.

9. Chronic constriction injury.

10. Capsaicin induced hyperalgesia and allodynia

11. Incision induced pain model

12. Chemotheraphy induced neuropathic pain.

13. Streptozocin induced diabetic neuropathic pain.

14. Adjuvant induced arthiritis in rats.

15. Monoiodo acetate induced arthiritis in rats.

16. TPA induced psoriasis.

Preclinical Screening of Novel Chemical Entities for efficacy and safety in

metabolic disorders by

1. STZ-induced diabetes in adult rats (Type-I)

2. High fat + STZ model (Type-II)

3. Nicotinamide +STZ model (Type-II)

4. Multiple low dose STZ-induced diabetes in mice (Type-I)

5. Oral glucose tolerance test in mice, rats

6. High fat diet studies in mice, rats

7. Bulimia nervosa (Binge eating study)

8. Acute food intake studies

Preclinical Screening of Novel Chemical Entities in Safety models by

Rota rod, GI safety models of gastric emptying, GI transit, GI secretion

and GI irritation, CVS.

Strength

> Strong scientific understanding of CNS diseases anatomy, physiology,

pharmacology..

> Significant experience outside of an academic and institutional setting

in a biotech or pharmaceutical company.

> Experience handling biological samples (tissues, plasma, serum) for

analytical purposes.

> Ability to handle biopharmaceutical compounds for in vivo and ex vivo

pharmacology studies.

> Extensive hands-on research experience and technical skills.

> Excellent organizational skills, record keeping and data presentation,

and capable of independently designing and executing experiments.

> Proven ability to generate high quality data in a timely manner to

facilitate data-driven decision making, as well as reports for internal

meeting.

> Excellent interpersonal and oral as well as written communications

skills.

> Excellent ability to collaborate with scientists internally and

externally to achieve the goals of the department.

> Hands on in vivo experience with animal models of obesity and diabetes.

KEY SKILLS

> Scientific data compilation, Statistical analysis and Report writing.

> Preparation of draft / final protocols & Reports.

> Having experience in GLP documentation and acted as Study Director for

number of Studies.

> Expert in handling of preclinical species viz., Rat, Mice and Guinea

pig,Rabbit etc.

> Expert in Randomising the animals and also expert in dosing of various

animal species by different routes of administration like p.o., i.p.,

s.c., i.v. etc.

> Blood collections through retro orbital pad rupture, cadiac puncture and

tail vein.

> Expert in canulating jugular, carotid artery veins.

> Handful of experience in setting up & Optimisation of methods useful in

preclinical screening of Novel Chemical Entities.

> Expert in handling of Dynamic plantar aesthesiometer, Randall selitto,von

frey filaments.

> Proficiency in data base and Statistics like Graph pad prism 4.0 & 5.0

> Proficiency in Microsoft office and Video Tracking System (TSE) Smart

(Pan lab) for recording Animal Behaviour.

MASTERS THESIS

Title: "STUDIES ON POLYMORPHISMS OF MDR1 GENE IN CERVICAL CANCER CASES AND

CONTROLS"

The significance of the human multi drug resistance gene (MDR1) G1199A

Polymorphism, resulting in a Ser400Asn modification in P-glycoprotein (P-

gp).G1199A polymorphism (amino acid change Ser400Asn) alters P-glycoprotein

(P- gp)-dependent Trans epithelial permeability and uptake kinetics of HIV

protease inhibitors.

From the study we conclude that there is high prevalence of the G-A

transition at 1199 codon in exon 11 of mdr1 gene in cervical cancer cases.

Also we conclude that GA genotype has significant correlation with cancer

development and the highest percentage of mutant mdr1 genotype at 1199

codon at the age of 41-50 years range and these polymorphisms during the

lifetime of the individuals, and the event of tumorogensis leads to further

accumulation of this polymorphism.

Methods and equipments used:

Isolation of DNA.

Polymerase chain reaction.

Agarose gel electrophoresis.

Polyacrylamide gel electrophoresis.

KEY PUBLICATIONS AND POSTERS

Polymorphisms of MDR1 gene in cervical cancer cases and controls

P. Srikanth Y. Sunitha*, Madhurilatha Thadanki, Y. Ramu and A. Kishore

Babu international journal of research in pharmacy and chemistry -2011

Procognitive properties of SUVN-G1031, a novel selective H3receptor

antagonist in rat models of cognitive deficits.

D. Shanmuganathan, M. R. Babu, K. Baburao, r. Abraham, p. Jayarajan, s. L.

Jabaris, v. Goura, r. Yaramasu, k. Marimuthu, v. Kandikere, n. R. Muddana,

a. Shinde, a. Deshpande, a. R. Dwarampudi, R Nirogi; Society For

Neurosecience (SFN), San Diego-2010.

Chronic high fat diet consumption: Implications on cognitive function.

d. Shanmuganathan, B. Kancharla, r. Medapati, g. V. Ramalingayya, r.

Abraham, s. Mohanty, r. Yaramasu, r. Nirogi; Washington-2011

Effect of various cognitive enhancers in acquisition task of radial arm

maze.

Pradeep jayarajan, Ramakrishna Nirogi, dhanalakshmi Shanmuganathan,

Venkatesh Goura, Ramu Yaramasu, Kannadasan Marimuthu, Suven life sciences,

Hyderabad. International conference on Alzheimer,s Disease-2012.

Pharmacokinetic-pharmacodynamic relationships of amnesic effects of

scopolamine in Rats.

Ramakrishna Nirogi, Vijay Benade,Vishwottam Kandikere,ranjith kumar

ponnamaneni,LakshmiNarayana Manjunath,Ramanatha Saralya, Gopinadh

Bhyrapuneni,Pradeep Jayarajan, Renny Abraham, Ramu Yaramasu, Saravana Kumar

Marimuthu,Swayam sampurna Mohanthy, Suven life sciences, Hyderabad

International conference on Alzheimer,s Disease-2012.

Pro-cognitive properties of SUVN-D1108121 a potent and selective 5-HT4

receptor partial agonist.

Ramakrishna Nirogi, Renny Abraham, Vijay Benade, Gopinadh

Bhyrapuneni,Abinash Das, Arunkumar Manoharan, Ramu Yramasu, Anil Shinde,

Ramasastri Kambhampati,Adireddy Dwarampudi, Suven life sciences, Hyderabad

International conference on Alzheimer,s Disease-2012.

PERSONAL PROFILE

Gender: : Male

Marital Status : Married

Language Known : English, Telugu, Hindi, Kannada.

Hobbies : Internet surfing PubMed, Psychopharmacology,

Springer link, Nature

: Playing chess

Address for correspondence: c/o Nazar

Hessensgade 21,1th

2300 Copenhagen S

Denmark

Declaration:

I, hereby declare that the information furnished above is true

to the best of my knowledge.

Place : Denmark

Date :

Yours Sincerely

(Ramu yaramasu)

Contact this candidate